Clinical Trial Update: A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia [Phase 4]

View source ↗

Summary

Six-week randomized, double-blind, placebo-controlled trial evaluating suvorexant augmentation to antidepressant treatment in major depressive disorder with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia
• Major Depressive Disorder

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Institute for Advanced Medical Research, Alpharetta, GA | Conditions: Depression, Major Depressive Disorder | Phase 4 | Status: UNKNOWN